US Patent

US10799490 — Pharmaceutical compositions of therapeutically active compounds

Method of Use · Assigned to Agios Pharmaceuticals Inc · Expires 2035-03-13 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating cancer using compounds or pharmaceutical compositions described in the patent.

USPTO Abstract

Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.

Drugs covered by this patent

Tibsovo (IVOSIDENIB) · Servier

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3384`	—	Tibsovo

Patent Metadata

Patent number: US10799490
Jurisdiction: US
Classification: Method of Use
Expires: 2035-03-13
Drug substance claim: No
Drug product claim: Yes
Assignee: Agios Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.